Novel CDKs inhibitors for the treatment of solid tumour by simultaneously regulating the cell cycle and transcription control

References

• Ciceri P, Muller S, O'Mahony A, et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol 2014;10:305–12.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
   PubMed Web of Science ®Google Scholar
• Johnson LN, Lewis RJ. Structural basis for control by phosphorylation. Chem Rev 2001;101:2209–42.
   PubMed Web of Science ®Google Scholar
• Adams JA. Kinetic and catalytic mechanisms of protein kinases. Chem Rev 2001;101:2271–90.
   PubMed Web of Science ®Google Scholar
• Huang M, Shen AJ, Ding J, Geng MY. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol Sci 2014;35:41–50.
   PubMed Web of Science ®Google Scholar
• Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. Ca Cancer J Clin 2009;59:111–37.
   PubMed Web of Science ®Google Scholar
• Sun C, Bernards R. Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. Trends Biochem Sci 2014;39:465–74.
   PubMed Web of Science ®Google Scholar
• Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci 2015;36:422–39.
   PubMed Web of Science ®Google Scholar
• Baker SJ, Reddy EP. Targeted inhibition of kinases in cancer therapy. Mt Sinai J Med 2010;77:573–86.
   PubMedGoogle Scholar
• Krug M, Hilgeroth A. Recent advances in the development of multi-kinase inhibitors. Mini Rev Med Chem 2008;8:1312–27.
   PubMed Web of Science ®Google Scholar
• Asghar U, Witkiewicz AK, Turner NC, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 2015;14:130–46.
   PubMed Web of Science ®Google Scholar
• Peyressatre M, Prevel C, Pellerano M, Morris MC. Targeting cyclin-dependent kinases in human cancers: from small molecules to peptide inhibitors. Cancers 2015;7:179–237.
   PubMed Web of Science ®Google Scholar
• Deshpande A, Sicinski P, Hinds PW. Cyclins and cdks in development and cancer: a perspective. Oncogene 2005;24:2909–15.
   PubMed Web of Science ®Google Scholar
• Kalra S, Joshi G, Munshi A, Kumar R. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors. Eur J Med Chem 2017;142:424–58.
   PubMed Web of Science ®Google Scholar
• Harbour JW, Luo RX, Dei Santi A, et al. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999;98:859–69.
   PubMed Web of Science ®Google Scholar
• Romano G. Deregulations in the cyclin-dependent kinase-9-related pathway in cancer: implications for drug discovery and development. ISRN Oncol 2013;2013:1–14.
   Google Scholar
• Morales F, Giordano A. Overview of CDK9 as a target in cancer research. Cell Cycle 2016;15:519–27.
   PubMed Web of Science ®Google Scholar
• Wang S, Fischer PM. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci 2008;29:302–13.
   PubMed Web of Science ®Google Scholar
• Bose P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs 2013;22:723–38.
   PubMed Web of Science ®Google Scholar
• Vijayaraghavan S, Moulder S, Keyomarsi K, et al. Inhibiting CDK in cancer therapy: current evidence and future directions. Targeted Oncol 2018;13:21–38.
   PubMed Web of Science ®Google Scholar
• Sarosiek T. Inhibitors of cyclin-dependent kinases (CDK) – a new group of medicines in therapy of advanced breast cancer. Polski Merkuriusz Lekarski: organ Polskiego Towarzystwa Lekarskiego 2018;44:5–9.
   PubMedGoogle Scholar
• Heptinstall AB, Adiyasa I, Cano C, Hardcastle IR. Recent advances in CDK inhibitors for cancer therapy. Future Med Chem 2018;10:1369–88.
   PubMed Web of Science ®Google Scholar
• Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770–83.
   PubMed Web of Science ®Google Scholar
• DiPippo AJ, Patel NK, Barnett CM. Cyclin-dependent kinase inhibitors for the treatment of breast cancer: past, present, and future. Pharmacotherapy 2016;36:652–67.
   PubMed Web of Science ®Google Scholar
• Beaver JA, Amiri-Kordestani L, Charlab R, et al. FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res 2015;21:4760–6.
   PubMed Web of Science ®Google Scholar
• Shah A, Bloomquist E, Tang S, et al. FDA approval: ribociclib for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Clin Cancer Res 2018;24:2999–3004.
   PubMed Web of Science ®Google Scholar
• FDA OKs abemaciclib for ER+, HER2-breast cancer. Cancer Discov 2017;7:OF1.
   Web of Science ®Google Scholar
• Im SA, Mukai H, Park IH, et al. Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: results from the phase III, randomized PALOMA-2 study. J Glob Oncol 2019;5:1–19.
   Web of Science ®Google Scholar
• Meattini I, Desideri I, Scotti V, et al. Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer. Breast 2018;42:1–2.
   PubMed Web of Science ®Google Scholar
• Single-agent abemaciclib active in breast cancer. Cancer Discov 2016;6:809–10.
   Web of Science ®Google Scholar
• Hafner M, Mills CE, Subramanian K, et al. Multiomics profiling establishes the polypharmacology of FDA-approved CDK4/6 inhibitors and the potential for differential clinical activity. Cell Chem Biol 2019;26:1067–80.
   PubMed Web of Science ®Google Scholar
• Lukasik PM, Elabar S, Lam F, et al. Synthesis and biological evaluation of imidazo[4,5-b]pyridine and 4-heteroaryl-pyrimidine derivatives as anti-cancer agents. Eur J Med Chem 2012;57:311–22.
   PubMed Web of Science ®Google Scholar
• Singh U, Chashoo G, Khan SU, et al. Design of novel 3-pyrimidinylazaindole CDK2/9 inhibitors with potent in vitro and in vivo antitumor efficacy in a triple-negative breast cancer model. J Med Chem 2017;60:9470–89.
   PubMed Web of Science ®Google Scholar
• Cai D, Latham VM, Jr., Zhang X, Shapiro GI. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 2006;66:9270–80.
   PubMed Web of Science ®Google Scholar
• Surur AS, Schulig L, Link A. Interconnection of sulfides and sulfoxides in medicinal chemistry. Archiv Der Pharmazie 2019;352:e1800248.
   PubMed Web of Science ®Google Scholar
• Gupta P, Kim B, Kim SH, Srivastava SK. Molecular targets of isothiocyanates in cancer: recent advances. Mol Nutr Food Res 2014;58:1685–707.
   PubMed Web of Science ®Google Scholar
• Guo Q, Yu C, Zhang C, et al. Highly selective, potent, and oral mTOR inhibitor for treatment of cancer as autophagy inducer. J Med Chem 2018;61:881–904.
   PubMed Web of Science ®Google Scholar
• Li Y, Luo X, Guo Q, et al. Discovery of N1-(4-((7-cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide as a novel inhibitor targeting cyclin-dependent kinase 4/9 (CDK4/9) and histone deacetlyase1 (HDAC1) against malignant cancer. J Med Chem 2018;61:3166–92.
   PubMed Web of Science ®Google Scholar
• Chiu HC, Huang WR, Liao TL, et al. Mechanistic insights into avian reovirus p17-modulated suppression of cell cycle CDK-cyclin complexes and enhancement of p53 and cyclin H interaction. J Biol Chem 2018;293:12542–62.
   PubMed Web of Science ®Google Scholar
• Thangavel C, Boopathi E, Liu Y, et al. Therapeutic challenge with a CDK 4/6 inhibitor induces an RB-dependent SMAC-mediated apoptotic response in non-small cell lung cancer. Clin Cancer Res 2018;24:1402–14.
   PubMed Web of Science ®Google Scholar
• Aleem E, Arceci RJ. Targeting cell cycle regulators in hematologic malignancies. Front Cell Dev Biol 2015;3:16.
   PubMed Web of Science ®Google Scholar